肝纤维化定量
本文综述肝纤维化的发病机制、不同慢性肝病中肝纤维化的时空演变及肝活检严重度评估,并讨论影像生物标志物所测属性及其与肝纤维化的关系。肝纤维化定量对分期、疗效评估和预后判断重要,无创检测包括简易血清试验、血清试验组合和影像生物标志物,均以肝活检为参考标准验证。
要点
- 肝纤维化是慢性肝损伤的愈合反应,是慢性肝病长期肝脏相关临床结局最重要的单一决定因素。
- 肝活检有创且活检体积不足时存在采样误差,无创检测在临床中发挥重要作用。
- 弹性成像等影像生物标志物目前临床用作肝纤维化的替代标志物,其他影像生物标志物仍属研究阶段。
核心结论
- 无创检测以肝活检为参考标准验证,未来将用于几乎所有慢性肝病的评估,有创肝活检仅保留用于部分病例。
研究设计与样本
- 综述,未报告检索范围与纳入文献数量。
临床应用与阅片要点
- 理解影像生物标志物所测属性及其与肝纤维化的相关性,有助于腹部放射科医生理解无创检测的应用。
- 影像生物标志物评估可能在未来成为常规,了解肝纤维化发病机制很重要。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Liver fibrosis (LF) is the wound healing response to chronic liver injury. LF is the endpoint of chronic liver disease (CLD) regardless of etiology and the single most important determinant of long-term liver-related clinical outcomes. Quantification of LF is important for staging, to evaluate response to treatment and to predict outcomes. LF is traditionally staged by liver biopsy. However, liver biopsy is invasive and suffers from sampling errors when biopsy size is inadequate; therefore, non-invasive tests (NITs) have found important roles in clinical care. NITs include simple laboratory-based serum tests, panels of serum tests, and imaging biomarkers. NITs are validated against the liver biopsy and will be used in the future for evaluation of nearly all CLDs with invasive liver biopsy reserved for some cases. Both serum tests and some imaging biomarkers such as elastography are currently used clinically as surrogate markers for LF. Several other imaging biomarkers are still considered research and awaiting clinical application in the future. As the evaluation of imaging biomarkers will likely become the norm in the future, understanding pathogenesis of LF is important. Knowledge of properties measured by imaging biomarkers and its correlation with LF is important to understand the application of NITs by abdominal radiologists. In this review, we present a brief overview of pathogenesis of LF, spatiotemporal evolution of LF in different CLD, and severity assessment with liver biopsy. This will be followed by a brief discussion on properties measured by imaging biomarkers and their relationship to the LF.
引用
- Venkatesh, Torbenson. Liver fibrosis quantification. Abdom Radiol (NY). 2022. PMID: 35022806. doi:10.1007/s00261-021-03396-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。